Thomas Jonassen, MD, Chair
Thomas Jonassen is an experienced biotech entrepreneur, having founded a number of successful biotech companies. He is the former co-founder and Chief Science Officer of Action Pharma (sold to Abbvie in 2012), TXP-Pharma (main asset sold to Questcor Pharmaceuticals in 2015) and presently also serves as CSO at SynAct Pharma, a biotech company focused on novel therapeutics for inflammatory joint disorders. In addition to these roles, Dr. Jonassen is associate professor at the University of Copenhagen in the department of Cardiovascular Pharmacology and an honorary professor at William Harvey Research Institute at the Queen Mary University in London.
Mauro Perretti, PhD
Dr. Perretti is Professor of Immuno Pharmacology at Queen Mary University, London and Dean of Research, Barts and the London School of Medicine.
Professor Perretti has several inventions in the field of FPR2-agonists, including co-inventions of several of ResoTher Pharma´s lead compounds. He is a renowned scientist and has published extensively on the role of the naturally occurring peptide Annexin A1 in the resolution of inflammation. Professor Perrettti is the author of more than 300 highly cited publications and is a fellow at the British Pharmacological Society.
Oliver Soehnlein, MD/PhD
Dr. Soehnlein is Professor of Regulatory Mechanisms of Inflammation and Director of the Institute of Experimental Pathology (ExPat) at the University Hospital in Münster, Germany. He obtained is MD from the University of Erlangen (Germany) and his PhD from the Karolinska Institute in Stockholm (Sweden). Oliver Soehnlein has made several inventions aimed at controlling excessive inflammation and his research focuses on myeloid cell driven inflammation and its resolution in the field of cardiovascular pathologies. His seminal studies are published in leading journals including Nature, Circulation, and Science Translational Medicine.
Anthony Mathur, MD
Dr. Mathur is a clinical cardiologist and the Clinical Director for Interventional Cardiology at Barts Heart Centre where he leads the Cardiovascular Devices Hub at the Centre for Cardiovascular Medicine and Device Innovation. In addition, Dr. Mathur chairs the European Society of Cardiology’s Task Force on stem cells in cardiovascular disease. Dr. Mathur divides his time equally between clinical work, focusing on treatment of heart attack and management of patients with heart failure, and also runs an extensive research programme to develop new biological treatments for patients with heart disease.
Thomas Jonassen, MD
CHIEF SCIENCE OFFICER
Thomas Jonassen is an experienced biotech entrepreneur, having founded a number of successful biotech companies. He is the former co-founder and Chief Science Officer of Action Pharma (sold to Abbvie in 2012).
TXP-Pharma (main asset sold to Questcor Pharmaceuticals in 2015) and presently also serves as CSO at SynAct Pharma, a biotech company focused on novel therapeutics for inflammatory joint disorders. In addition to these roles, Dr. Jonassen is associate professor at the University of Copenhagen in the department of Cardiovascular Pharmacology and an honorary professor at William Harvey Research Institute at the Queen Mary University in London.
Mauro Perretti, PhD
Dr. Perretti is Professor of Immuno Pharmacology at Queen Mary University, London and Dean of Research, Barts and the London School of Medicine.
Professor Perretti has several inventions in the field of FPR2-agonists, including co-inventions of several of ResoTher Pharma´s lead compounds. He is a renowned scientist and has published extensively on the role of the naturally occurring peptide Annexin A1 in the resolution of inflammation. Professor Perrettti is the author of more than 300 highly cited publications and is a fellow at the British Pharmacological Society.
Oliver Soehnlein, MD / PhD
Dr. Soehnlein is Professor of Regulatory Mechanisms of Inflammation and Director of the Institute of Experimental Pathology (ExPat) at the University Hospital in Münster, Germany.
He obtained is MD from the University of Erlangen (Germany) and his PhD from the Karolinska Institute in Stockholm (Sweden). Oliver Soehnlein has made several inventions aimed at controlling excessive inflammation and his research focuses on myeloid cell driven inflammation and its resolution in the field of cardiovascular pathologies. His seminal studies are published in leading journals including Nature, Circulation, and Science Translational Medicine.
Anthony Mathur, MD
Dr. Mathur is a clinical cardiologist and the Clinical Director for Interventional Cardiology at Barts Heart Centre where he leads the Cardiovascular Devices Hub at the Centre for Cardiovascular Medicine and Device Innovation. In addition, Dr. Mathur chairs the European Society of Cardiology’s Task Force on stem cells in cardiovascular disease. Dr. Mathur divides his time equally between clinical work, focusing on treatment of heart attack and management of patients with heart failure, and also runs an extensive research programme to develop new biological treatments for patients with heart disease.
